ScholarIQanswers from OpenAlex & ORCID
Christopher Parker
ResearcherPublications, citations & collaboration network
Christopher Parker is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Christopher Parker have?
ScholarIQindexed works
Christopher Parker has 125 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Christopher Parker have?
ScholarIQcitation count
Christopher Parker has 19,429 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Christopher Parker?
ScholarIQh-index
Christopher Parker has an h-index of 49 in OpenAlex.
What is the i10-index of Christopher Parker?
ScholarIQi10-index
Christopher Parker has an i10-index of 73 in OpenAlex.
What is the OpenAlex record for Christopher Parker?
ScholarIQopenalex
The OpenAlex for Christopher Parker is on the source record.
What are the most-cited papers on Christopher Parker?
ScholarIQmost cited works
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James, Matthew R. Sydes, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, Melissa Spears, A.W.S. Ritchie, Christopher Parker, John M. Russell, Gerhardt Attard, Johann S. de Bono, William Cross, Robert J. Jones, George N. Thalmann, Claire Amos, David Matheson, Robin Millman, Mymoona Alzouebi, S. Beesley, Alison Birtle, Susannah Brock, Richard Cathomas, Prabir Chakraborti, Simon Chowdhury, Audrey Cook, Tony Elliott, Joanna Gale, Stephanie Gibbs, John D. Graham, John Hetherington, Robert Hughes, Robert Laing, Fiona McKinna, Duncan B. McLaren, Joe M. O’Sullivan, Omi Parikh, C. Peedell, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, Shaun Tolan, David Tsang, John Wagstaff, Mahesh Parmar
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James, Johann S. de Bono, Melissa Spears, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, A.W.S. Ritchie, Claire Amos, Clare Gilson, Robert J. Jones, David Matheson, Robin Millman, Gerhardt Attard, Simon Chowdhury, William Cross, Silke Gillessen, Christopher Parker, John M. Russell, Dominik Berthold, Chris Brawley, F. Adab, San Aung, Alison Birtle, Jo Bowen, Susannah Brock, Prabir Chakraborti, Catherine Ferguson, Joanna Gale, Emma Gray, Mohan Hingorani, Peter Hoskin, J.F. Lester, Zafar Malik, Fiona McKinna, Neil McPhail, Julian Money‐Kyrle, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher Parker, Nicholas D. James, Chris Brawley, Noel W. Clarke, Alex Hoyle, Adnan Ali, A.W.S. Ritchie, Gerhardt Attard, Simon Chowdhury, William Cross, David P. Dearnaley, Silke Gillessen, Clare Gilson, Robert J. Jones, Ruth E. Langley, Zafar Malik, Malcolm D. Mason, David Matheson, Robin Millman, John M. Russell, George N. Thalmann, Claire Amos, Roberto Alonzi, Amit Bahl, Alison Birtle, Omar Din, Hassan Douis, Chinnamani Eswar, Joanna Gale, Melissa Gannon, Sai Jonnada, Sara Khaksar, J.F. Lester, Joe M. O’Sullivan, Omi Parikh, Ian Pedley, Delia Pudney, D.J. Sheehan, Narayanan Srihari, Anna Tran, Mahesh Parmar, Matthew R. Sydes
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, Jeremy Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
Sten Nilsson, Lars Franzén, Christopher Parker, Christopher Tyrrell, René Blom, Jan Tennvall, Bo Lennernäs, Ulf Petersson, Dag Clement Johannessen, M. Sokal, K. Pigott, Jeffrey Yachnin, Michael Garkavij, Peter Strang, Johan Harmenberg, B. Bolstad, Øyvind S. Bruland